CA-SKYHIVE/DEUTSCHE
11.4.2022 13:02:07 CEST | Business Wire | Press release
SkyHive, a workforce technology innovator that delivers powerful insights for improved human capital management (HCM), today announced that Deutsche Bank, Germany’s leading bank, has made a sizable equity investment in the company via its strategic Corporate Venture Capital unit. The funding coincides with SkyHive’s European incorporation and increasing demand from multinational customers.
Michael Ilgner, Global Head of HR & Real Estate at Deutsche Bank, said: “Using data intelligently and with purpose will take human capital management to the next level. SkyHive is addressing a key talent shortage issue observed across all industries and particularly prevalent in financial services. Its value proposition of providing employers with a better understanding of the skills of their workforce and in the market paves the way for improved resource management, workforce upskilling, and employee retention.”
Gil Perez, Chief Innovation Officer at Deutsche Bank and Head of Deutsche Bank Corporate Venture Capital, said: “We are delighted to invest, partner and collaborate with SkyHive. Deutsche Bank’s digital transformation has accelerated the pace and scale we need to upskill our workforce, attract, and recruit the best talent in the market. Our ability to effectively and continually invest in our current and future employees is an integral part of our digital transformation.”
In addition to the investment, SkyHive has invited Karen Meyer, Chief Operating Officer for Deutsche Bank’s HR organization, to participate in SkyHive’s Board of Directors meetings in a non-voting observer capacity.
SkyHive.ai, a Certified B Corporation, combines its real-time, global labor market data with transparent and unbiased artificial intelligence to give companies, government and educators actionable insights into their workforce’s current and emerging skills, skills gaps, industry benchmarks and reskilling options. SkyHive uses a two-pronged approach: skills-first applications and extensible platforms that normalize skills intelligence for companies across existing HCM ecosystems. For individuals, SkyHive’s Skills Passport provides data, insights and upskilling options to ensure users’ skills stay relevant, both today and well into the future.
“Human capital is by far the most untapped potential in today’s modern age,” said SkyHive Founder and CEO Sean Hinton. “Enterprises and communities that are alert to the advancements in strategic workforce solutions can radically transform top and bottom-line growth trajectories by unleashing their workforce’s full capacity. Who you hire, where you hire, what you pay, who you deploy and how you compete are just a few examples of key business decisions that hinge on a deep, continuous and accurate understanding of your constituents’ skills. Our technology uniquely enables this mission-critical capability, and therefore was a strong rationale for Deutsche Bank’s investment.”
The investment from Deutsche Bank will support SkyHive’s growing global operations, particularly the company’s continued expansion in the European market. SkyHive also maintains ongoing partnerships with the likes of World Economic Forum, Workday and Accenture.
About SkyHive
SkyHive is a Certified B Corporation and software provider of global workforce intelligence technology, optimizing labor market efficiencies in real-time for companies, communities, and national economies. Leading enterprises use SkyHive’s cloud-based applications and platforms to power the future of work at its most granular level: skills. SkyHive’s Quantum Labor Analysis™ has been recognized by the World Economic Forum, Gartner, and Forbes for leading efforts in ethical AI and its positive impact on labor economies worldwide. For more information, visit www.skyhive.ai .
About Deutsche Bank
Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific. For more information, visit www.db.com .
About Deutsche Bank Corporate Venture Capital
Deutsche Bank Corporate Venture Capital (CVC) is a cross-divisional & global activity to support startups and entrepreneurs. For more information, visit db.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom